

Optimized broth microdilution plate methodology for drug susceptibility testing of *Mycobacterium tuberculosis* complex



World Health
Organization

**Optimized broth microdilution plate methodology for
drug susceptibility testing of *Mycobacterium*
tuberculosis complex**

Optimized broth microdilution plate methodology for drug susceptibility testing of *Mycobacterium tuberculosis* complex

ISBN 978-92-4-004741-9 (electronic version)

ISBN 978-92-4-004742-6 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Optimized broth microdilution plate methodology for drug susceptibility testing of *Mycobacterium tuberculosis* complex. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	iv
Abbreviations.....	vi
1 Rationale for an optimized broth microdilution plate	1
2 Design considerations	7
2.1 Main limitations of MYCOTB(I) plate	7
2.2 Overview of other BMD plates	8
2.3 Upper limit of drugs on optimized BMD plate	8
2.4 Drug priorities for inclusion on optimized BMD plate	9
2.5 Tentative layout of an optimized BMD plate	15
3 Methodological considerations.....	17
3.1 Measures to ensure high-quality BMD testing.....	17
3.2 Plate reading	18
4 Conclusion.....	20
5 References	22

List of figures

FIGURE 1. ATU FOR HYPOTHETICAL MIC DISTRIBUTIONS OF SUSCEPTIBLE AND RESISTANT STRAINS.....	3
FIGURE 2. TENTATIVE LAYOUT OF AN OPTIMIZED BMD PLATE.....	9

List of tables

TABLE 1. OVERVIEW OF SIX COMMERCIAL OR RESEARCH BMD PLATES BY TFS COMPARED WITH EUCAST REFERENCE METHOD.....	4
TABLE 2. OVERVIEW OF CURRENT <i>MYCOBACTERIUM TUBERCULOSIS</i> H37Rv ATCC 27294 QC RANGES AND ECOFFs/CCs FOR BMD PLATES.....	6
TABLE 3. COMPARISON OF LFX AND MFX MICs FOR KEY RESISTANCE MECHANISMS.	12
TABLE 4. COMPARISON OF KAN AND AMK MICs FOR KEY RESISTANCE MECHANISMS.....	14

Acknowledgements

The development of this document was led by Nazir Ismail with input from Alexei Korobitsyn, Matteo Zignol and Karin Weyer, under the overall guidance of Tereza Kasaeva (WHO Global TB Programme), based on an analytical report on the use of broth microdilution plates prepared by Claudio Köser (University of Cambridge, United Kingdom of Great Britain and Northern Ireland), and consensus at a Technical Expert Group meeting convened by WHO on 25 February 2020, in Geneva, Switzerland.

Members of the WHO Technical Expert Consultation Group

Lynette Berkeley (US Food and Drug Administration, United States of America), Daniela Cirillo (San Raffaele Scientific Institute, Italy), Derrick Crook (University of Oxford, United Kingdom of Great Britain and Northern Ireland), Kelly Dooley (Johns Hopkins University School of Medicine, United States of America), Gerry Davies (Liverpool School of Tropical Medicine, United Kingdom of Great Britain and Northern Ireland), Bernard Fourie (University of Pretoria, South Africa), Philip Fowler (University of Oxford, United Kingdom of Great Britain and Northern Ireland), Christopher Gilpin (International Organization for Migration, Switzerland), Patricia Hall (Centers for Disease Control and Prevention, United States of America), Rumina Hasan (Aga Khan University, Pakistan), Marguerite Massinga Loembé (Africa Centres for Disease Control and Prevention, Gabon), Charles Peloquin (University of Florida, United States of America), Max Salfinger (University of South Florida, United States of America), Thomas Schön (Linköping University, Sweden), Thomas Shinnick (Independent consultant, United States of America), Sabira Tahseen (National Reference Laboratory, Pakistan), Gabriela Torrea (Prince Leopold Institute of Tropical Medicine, Belgium), and Armand Van Deun (Prince Leopold Institute of Tropical Medicine, Belgium).

Members of the WHO External Review Group

Derek Armstrong (Johns Hopkins University, United States of America), Rossella Baldan (FIND, Switzerland), Emmanuelle Cambau (National Reference Center for Mycobacteria and Antimycobacterial Resistance, France), Peter Keller (University of Bern, Switzerland), Scott Heysell (University of Virginia, United States of America), Florian Maurer (Research Center Borstel, Germany), Shaheed Omar (National Institute of Communicable Diseases, South Africa), Nikki Parrish (Johns Hopkins University, United States of America), James Posey (Centers for Disease Control and Prevention, United States of America), Juliano Timm (TB Alliance, United States of America), Nancy Wengenack (Mayo Clinic, United States of America), and Jim Werngren (Public Health Agency of Sweden, Sweden).

Observers

Toby Hampshire (Thermo Fisher Scientific, United Kingdom of Great Britain and Northern Ireland), Koné Kaniga (Johnson & Johnson, United States of America), Mischka Moodley (Otsuka Novel Products GmbH, Germany) and Brigit Quinn (Becton Dickinson, United States of America).

Technical resource person

Claudio Köser.

Major data contributors

Daniela Cirillo, Alamdar Hussain (National Reference Laboratory, Pakistan), Faisal Masood (National Reference Laboratory, Pakistan), Andrea Spitaleri (San Raffaele Scientific Institute, Italy), and Sabira Tahseen.

Acknowledgement of financial support

This work was commissioned by and funded in part by WHO. The United States Agency for International Development and the Federal Government of Germany covered a proportion of Claudio Köser's salary for this report as part of his work for the European Laboratory Initiative, led by Soudeh Ehsani (WHO Regional Office for Europe, Denmark). Claudio Köser is research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. Moreover, we thank Gunnar Kahlmeter and Erika Matuschek (European Committee on Antimicrobial Susceptibility Testing Development Laboratory, Sweden) for their advice and the European Society of Clinical Microbiology and Infectious Diseases for support provided through an observership.

Declaration and management of conflict of interest

All the contributors completed a WHO Declaration of Interest form. All stated declarations of interest were evaluated by members of the Steering Group for the existence of any possible financial conflict of interest which might warrant exclusion from membership of the Technical Expert Consultation Group or from the discussions as part of the consensus process. Intellectual conflict of interest was not considered for exclusion from membership of the Group, as broader expertise on DST methods for MTBC was considered as criteria for the selection. In addition, the diversity and representation in the Groups was large enough to balance and overcome any potential intellectual conflict of interest. During the consensus development process and the meeting, any emergence of intellectual conflict of interest was monitored by the Chair and there was no perceived intellectual conflict of interest identified during the meeting.

Abbreviations

7H9 = Middlebrook 7H9
AMK = amikacin
ATU = area of technical uncertainty
BDQ = bedaquiline
BMD = broth microdilution
CAP = capreomycin
CB = clinical breakpoint (as defined by WHO rather than EUCAST)
CC = critical concentration
CFZ = clofazimine
CI = exact binomial confidence interval
CLA = clavulanic acid
CLSI = Clinical & Laboratory Standards Institute
CP = critical proportion
DCS = D-cycloserine
DLM = delamanid
DMSO = dimethyl sulfoxide
DST = drug-susceptibility testing
ECOFF = epidemiological cut-off value
EMB = ethambutol
ETO = ethionamide
EUCAST = European Committee on Antimicrobial Susceptibility Testing
FQ = fluoroquinolone
GC = growth control
gDST = genotypic drug susceptibility testing
gWT = genotypically wild-type
HLR = high-level resistance/resistant
H37Rv = *Mycobacterium tuberculosis* H37Rv ATCC 27294
IMP-CLN = imipenem-cilastatin
IFUs = instructions for use
INH = isoniazid
ISO = International Organization for Standardization
LFX = levofloxacin
LLR = low-level resistance/resistant
LoF = loss-of-function
LZD = linezolid
KAN = kanamycin
MDR = multidrug-resistant
MFX = moxifloxacin
MGIT = BACTEC™ Mycobacterial Growth Indicator Tube™
MIC = minimum inhibitory concentration
MPM = meropenem
MTBC = *Mycobacterium tuberculosis* complex
MYCOTB(I) = Sensititre™ MYCOTB or Sensititre™ MYCOTBI
OADC = oleic acid albumin dextrose catalase

OFX = ofloxacin
PAS = *para*-aminosalicylic acid
pATU = potential area of technical uncertainty
pCB = potential clinical breakpoint
pDST = phenotypic drug susceptibility testing
pECOFF = potential epidemiological cut-off value
pQC = potential quality control
PMD = pretomanid
PTO = prothionamide
pWT = phenotypically wild-type
PZA = pyrazinamide
QC = quality control
R = resistance/resistant
RFB = rifabutin
RIF = rifampicin
RR = rifampicin resistant
RRDR = rifampicin resistance-determining region
RPT = rifapentine
S = susceptible/susceptibility
SOP = standard operating procedure
STR = streptomycin
TB = tuberculosis
TEG = Technical Expert Group
TFS = Thermo Fisher Scientific
TZD = terizidone
WHO = World Health Organization
XDR = extensively drug-resistant

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31003

